echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Blood: The Otub1/c-Maf axis may be a potential therapeutic target for multiple myeloma.

    Blood: The Otub1/c-Maf axis may be a potential therapeutic target for multiple myeloma.

    • Last Update: 2020-09-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Cancer-causing transcription factor c-Maf has been considered an ideal therapeutic target for multiple myeloma (MM), but how this can be achieved remains unclear.
    the study, the researchers found that the Otub1/c-Maf axis could be a potential target.
    Otub1, which belongs to the OTU family of de-ubibinases, has been found to interact with c-Maf.
    Otub1 can abolish polypronination of c-Maf K48 connections, preventing degradation and enhancing their transcriptional activity.
    specifically, this de-ubitinization activity depends on its Lys71 and N ends, but not on UCE2O, a known c-Maf E2.
    Otub1 promotes MM cell survival and MM tumor growth.
    , silence Otub1 can lead to c-Maf degradation and c-Maf expressive MM apoptosis.
    , the Otub1/c-Maf axis may be a therapeutic target for MM.
    To explore this hypothesization, the researchers screened FDA-approved drugs and natural products using c-Maf-identified original fluorin-driven reporting trials and found that the original strong glycoside, anthromosine C (LanC), prevented C-Maf de-ubibination and induced its degradation by interfering with the interactions between Otub1 and C-Maf.
    further experiments have shown that LanC inhibits c-Maf transcription activity, induces c-Maf expressive MM apoptosis, inhibits MM growth, and prolongs the overall survival of mouse models without significant toxicity.
    , the study suggests that Otub1 is a new de-ubibinase for c-Maf, suggesting that Otub1/c-Maf may be a potential therapeutic target for MM.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.